Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 22Neoplasms 5Neoplasm Metastasis 2Urachal cancer 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Cancer Metastatic 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Octreotide 4Everolimus 4Capecitabine 3Temozolomide 2Melphalan 2Biological Therapy 2vatalanib 1temsirolimus 1romidepsin 1regorafenib 1motesanib diphosphate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Leucovorin 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Gefitinib 1Fluorouracil 1Filgrastim 1Cytokines 1Complementary Therapies 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Islet Cell × folfirinox × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡